BioSpace News Archive

Mettler-Toledo International Inc. announced first quarter results for 2023.

ACELYRIN, INC. today announced the pricing of its upsized initial public offering of 30,000,000 shares of common stock at a price to the public of $18.00 per share.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50 per share, before underwriting discounts and commissions.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employee’s acceptance of employment with the company.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the pricing of its underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $22.00.

OpGen, Inc. announced the closing of its previously announced public offering of an aggregate of 4,495,825 shares of its common stock and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share and accompanying warrant.

Akumin Inc. will host a conference call at 8:30 a.m. Eastern Time, May 11, 2023, to discuss its first quarter 2023 financial results.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced its new organizational structure designed to accelerate innovation and commercialization.

Zynex, Inc., announced the pricing of its previously announced private offering of $52.5 million aggregate principal amount of 5.00% convertible senior notes due 2026 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Immuneering Corporation, a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, reported financial results for the first quarter ended March 31, 2023, and provided business updates.